[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Pengyuan Liu\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100535278","phase-2-clinical-application-of-near-infrared-whole-body-heat-shock-multimodal-technique-in-treatment-of-castration-resistant-prostate-cancer-100535278",false,"NCT06249750","Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer","Inclusion Criteria:\n\n* Histopathologically confirmed diagnosis of PC and clinically confirmed diagnosis of CRPC;\n* Complete and reliable medical history and medical records;\n* No other primary tumors except CRPC;\n* Blood tests, liver function, renal function and electrocardiogram are basically normal;\n* Patients with ECOG score 0\\~3, aged ≥18 years and \\\u003C90 years old;\n* Patients with good compliance, able to accept regular follow-up.\n\nExclusion Criteria:\n\n* History of malignant tumor other than PC within the past 5 years;\n* Severe abnormalities in the patient's laboratory indices may jeopardize patient safety or compromise this study;\n* Accompanied by severe underlying diseases that cannot tolerate this therapy;\n* With acute diseases, such as acute infection, active bleeding;\n* Those who have recently participated in other clinical trials and have not passed the washout period;\n* Those who cannot tolerate systemic heat stress, such as claustrophobic patients;\n* Those who have a history of allergy to the drugs used in the trial;\n* Patients with other reasons for not being able to be enrolled in the study, according to the study doctor.","MALE","18 Years","90 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","In this study, we propose to use the combination of ET-SPACE NIR irradiation whole-body thermal stimulation, ICI (Tislelizumab), and RTK inhibitor (Anlotinib) in the multimodal treatment of CRPC.",[26],"Metastatic Castration-resistant Prostate Cancer (CRPC)",[28],"hyperthermia, immune checkpoint inhibitor, RTK inhibitor, CRPC","RECRUITING","2024-01-31",{"date":32,"type":33},"2024-02-08","ACTUAL",{"date":35,"type":33},"2024-01-01",{"date":37,"type":20},"2026-12-31",{"name":39,"class":40},"Pengyuan Liu","OTHER",""]